F-20 leads military industry stocks to take off

As the two centuries of the founding of the party and the army are approaching, there will be more catalysts for the defense and military industry, and “a hundred years of change” will inevitably accelerate the modernization of our army. Last weekend, CCTV’s military channel reported that the second unit equipped with the J-20 was officially made public. It was the first group of the Air Force to form, participate in the war, and win the first “Strong Army Pioneer Brigade”. Compared with the J-20 equipped by the “Wang Hai Brigade”, the J-20 equipped by the “Strong Army Pioneer Brigade” has undergone many improvements, especially the engine is replaced with a domestic turbofan-10 engine, which means that the J-20 has been realized. Fully localized.

Affected by this news, the national defense and military industry sector rose heavily in early trading today. The sector index rose for the third consecutive day and hit a new high in nearly three and a half months. Dongtu Technology’s 20% daily limit, Eleda, Bright, and New Research , Anhui Technology, etc., the daily limit may rise by more than 10%. Military ETF funds also rose today, leading the rise.

The F-20 can achieve 100% localization rate, even if it is not easy in the world, except for the F-20, currently only the United States can achieve 100% localization of the fifth-generation fighter, even Russia and France currently Russia lacks high-performance electronic equipment and optical equipment, and needs to import gallium arsenide semiconductor materials from South Korea. Although France can develop Rafale fighters, France does not have the technology to manufacture ejection seats and needs to import ejection seats from the United Kingdom. chair.

Ai Leda focuses on the field of aviation manufacturing, mainly engaged in the production of aircraft structural parts and engine parts. Since the establishment of the company for more than ten years, it has accumulatively participated in the development and production of a variety of models involving more than 3000 aviation parts. On the investor interactive platform, investors have repeatedly asked whether the company’s products are available for the F-20, H-20, and Yun-20 models. Eleda did not respond directly on the grounds that military secrets were involved.

But this does not prevent investors from showing their love for Philharmonic. In 2020, Philharmonic has soared by 271%, and it has risen by more than 30% this year. Today, stimulated by the good news, the intraday straight line pulled up to the 20% daily limit. Beijing Capital Capital increased its holdings of Philharmonic by more than 50% last Friday, and its number of shares hit a four-month high.

Guohai Securities stated that the continuous installation of the J-20 aircraft will further enhance the air force’s comprehensive combat capabilities, and also shows that the national defense construction continues to advance, downstream demand is strong, and the aviation industry chain continues to rise. The 14th Five-Year Plan period is a critical period for achieving the “Hundred Years of Military Struggle” in 2027. The military industry has entered a period of accelerated growth, the industry’s production capacity is expanding, and the fundamentals of many high-quality segments will continue to improve. It is recommended to focus on such fields as missiles, military aircraft and aero-engine industrial chains, new materials for military industry with high upstream prosperity, military electronics, and military information technology.

Capital rallies to reduce chip stocks

Electronic technology stocks continued to strengthen in early trading. The semiconductor sector index hit a record high during the session, the gallium nitride sector index also hit a record high, the chip sector index hit a new high in the past year, and the lithography machine sector index approached a new high this year. The daily limit of Liyuan Information is 20%, and the daily limit of Hanwei Technology, Jingsheng Electromechanical, and Jingchen shares may rise by more than 10%.

As the problem of chip shortages continues to intensify, major domestic and foreign semiconductor manufacturing companies have raised their capital expenditure plans, vigorously expanding production capacity, and increasing prices, shortages, and expansion into “high-frequency vocabulary.” Domestic and foreign companies have raised prices in various aspects of semiconductors, but the contradiction between chip supply and demand is still prominent, which is eventually transmitted to the production links of physical enterprises such as automobiles and mobile phones. The market predicts that this round of the semiconductor industry boom cycle will last at least until the end of 2022.

However, investors should focus on the fact that at present, experts have warned that chip manufacturers may have excessive hunger marketing and large-scale production expansion, and there may be a crisis of chip surplus in the future. And market capital is also constantly flowing out taking advantage of the stock price surge. According to Wind statistics, starting from Qunengdi, the National Integrated Circuit Industry Investment Fund has successively reduced its holdings in high-quality companies such as North China Chuangchuang and Zhaoyi Innovation. Recently, Weir shares and others have also announced information on shareholder reductions. In addition, in just four trading days last week, the net outflow of chips and semiconductor-related ETFs reached nearly 5 billion yuan.

Beijing Capital Securities stated that the global core shortage has allowed the industry and capital markets to re-understand the semiconductor manufacturing process, especially semiconductor foundries and IDM-mode semiconductor manufacturers. Companies with fabs will have greater and greater say in future development, and the higher the differentiation, the better, and the valuation given by the capital market will also become higher and higher. Semiconductor is the core technology. To buy a technology company, you must have technical strength, and be able to continuously launch new products, and new products can be recognized by the market to bring income.

Cross-border “drinking” Zhongxing Fungus Industry Daily Limit

How hot the liquor industry is, companies that grow edible fungi must also acquire liquor assets.

On the evening of June 20, Zhongxing Fungus Industry (002772) announced that in order to promote the development of the company’s dual main businesses and increase new profit growth points, the company plans to acquire Liu Jian and Liu Liangyue’s Shengjiao Wine in Maotai Town, Guizhou, in cash. Industry Co., Ltd. (referred to as “Shengjiao Wine Industry”) 100% equity.

Stimulated by the news, on June 21, Zhongxing Fungus Industry had a bid price limit. As of the noon close, the number of orders exceeded 1.15 million, reported at 9.64 yuan, with a total market value of 3.55 billion yuan.

According to the announcement, Shengjiao Wine Industry is located in the core production area of ​​7.5 square kilometers of Maotai-flavored liquor in Maotai Town, Renhuai City, China. Since its establishment, it has focused on the research and development, production and sales of Maotai-flavored liquor. One of the wine storage companies. The owner of Shengjiao Liquor’s product is the “Shengjiao” series of Maotai-flavored liquor. After years of development, Shengjiao Liquor has achieved a national distribution of sales channels and is one of the main manufacturers of Maotai-flavored liquor in my country.

Zhongxing Fungus Industry is a modern agricultural enterprise specializing in the research and development, factory cultivation and sales of edible fungi. The main products are Flammulina velutipes and Agaricus bisporus fresh products. Judging from the current main business layout, Zhongxing Fungi is determined to “drink” across the border. Zhongxing Fungus is not the first company to be the first Zhongshengjiao Wine Company.

In October last year, *ST Garden City announced that it planned to acquire 100% equity of Shengjiao Winery and raise matching funds by issuing shares and paying cash. Subsequently, the restructuring inquiry letter from the Shanghai Stock Exchange followed one after another. The core question was to explain the reason for the sharp increase in the performance of Shengjiao Wine Industry.

One month later, in November last year, *ST Park City stated that the transaction company and the target party could not reach an agreement on the valuation of the target company and terminated the acquisition of 100% of the shares of Shengjiao Wine Industry.

It is worth mentioning that in the four trading days from June 15th to 18th, the stock price of Zhongxing Fungi Industry rose successively, with a cumulative increase of 12.16% in the interval. A person in the liquor industry believes that cases of cross-border liquor making in the capital market are not uncommon, but there are many losers. There is still some suspense whether the acquisition plan can be successfully completed. The company also reminded investors in the announcement that the equity purchase agreement has not been formally signed, and it is not yet possible to predict the impact on the company’s operating results.

The concept of medical beauty is active again

The concept of medical beauty was active again on the 21st. As of press time, Harbin Sanlian’s daily limit, Langzi shares rose by more than 8%, Jiangsu Wuzhong, Kaineng Health, Lafang Jahwa, etc. rose by more than 6%, Yihua Health, Gold Rabbi , Aimeike, Huaxi Biology, Haohaishengke, etc. rose more than 5%.

On the news, recently, eight departments including the National Health Commission, the Office of Cyberspace Affairs, the Ministry of Public Security, the General Administration of Customs, the Market Supervision Bureau, the Post Office, the Food and Drug Administration, and the Bureau of Traditional Chinese Medicine jointly issued the “Special Rectification Work Plan for Combating Illegal Medical Beauty Services.” , Decided to jointly carry out related rectification work from June to December 2021. The rectification includes four aspects: (1) Strictly crack down on illegal medical aesthetics-related activities; (2) Strictly standardize medical aesthetics service behavior; (3) Severely crack down on illegal drug manufacturing and sales activities; (4) Severely investigate and punish illegal advertisements and the Internet information.

In this regard, CITIC Securities pointed out that remediation may affect some demand in the short term, but after dynamic rebalancing, market demand will shift to authentic licensed and formal medical aesthetics terminals; medical aesthetics accidents and disputes will decrease, and public trust will increase. It will promote the expansion of demand in the entire market and benefit the entire industry. The rapid expansion of the medical and aesthetic industry and supervision and remediation will help “good money drive out bad money.”

At the Fosun Pharma’s shareholders’ meeting held last week, Fosun Pharma stated thatBioNTechThe co-developed new crown mRNA vaccine Fubitai is still waiting for approval. At present, the approval process for pharmacy is basically completed, and the approval requirements and materials to be carried out in the follow-up have basically been sorted out.

Fosun Pharma: mRNA Covid-19vaccineAwaiting approval, the localized production line will be completed in August

Wu Yifang, Chairman of Fosun Pharma, revealed that “mRNA is a brand-new technical route. Under approval,countryThe Food and Drug Administration has some groundbreaking things to do, and we conducted in-depth exchanges throughout the process.countryThe Food and Drug Administration has given a lot of guidance and feedback is very fast. “It is understood that the matters required for the pharmacy-related conditional approval have been basically completed, and the subsequent conditional research and clinical requirements to be carried out are basically clear.

At the general meeting of shareholders, Fosun Pharma revealed thatBioNTechTechnology transfer and equipment ordering are already underway.BioNTechDispatchedexpertI have gone to the Jinshan plant in Shanghai to work with the Fosun Pharma team. Both parties have a daily meeting on various professional working groups. The localized production line is expected to be completed in August,beginnormal production.

Source: Network

Some people in the industry have put forward a point of view that Fosun Pharma and Germany’sBioNTechIt belongs to the joint venture agency model, and its essence is to exchange technology for the market.

As early as May 9, Fosun Pharma issued a major announcement stating that its holding subsidiary Fosun PharmaBioNTechInvest in the establishment of a joint venture company to realize the new mRNA crownvaccineLocalized production and commercialization of products.

At the beginning of last year, the two parties signed a license agreement, agreed to pay a license fee and pay a sales commission based on a certain percentage of the product’s annual gross profit.forGuaranteeChinese market mRNA Covid-19vaccineSupply, Fosun Pharmaceutical Industry andBioNTechSigned the “License Agreement Amendment One” on December 15, 2020, to promote mRNA COVID-19 in stages such as the import of finished products, the import of large-package preparations in China (excluding Hong Kong, Macao and Taiwan), and localized production.vaccineChina sales and supply reached an agreement.In order to further implement the relevant mRNA new crown in the “License Agreement Amendment One”vaccineArrangements for localized production, both partiesup to dateThe announcement announced the signing of the “Terms”, the establishment of a joint venture company, and an agreement that Fosun Pharmaceutical Industry should provide an annual production capacity of up to 1 billion doses of mRNA.vaccineProduction facilities and injected the facility as part of the capital contribution into the joint venture company.

onvaccineFor subsequent commercialization issues, the two parties agreed that the joint venture company will hire an affiliate of Fosun Pharmaceutical Industry as the CSO to provide mRNA new crowns in China (excluding Hong Kong, Macao and Taiwan)vaccineMarket and sales services, and pay corresponding fees to the CSO in accordance with the contract.

Subsequently, at the beginning of 2021, the BNT162b2 vaccine (Fobitai) was approved for emergency use in the Hong Kong Special Administrative Region and Macau Special Administrative Region respectively, and was used in the vaccination programs of the above-mentioned two regional governments in March.

According to CCTV News, as of June 14th, 31 provinces, municipalities (including the Corps) across the country had cumulatively reported vaccination against the new crownvaccineThe number of doses exceeded 900 million, even if Fosun Pharma’svaccineWhen approved, how much market will be left to it is a question of great concern to many investors.

There are barriers to the production technology of mRNA vaccines entering the sprint stage

At present, the domestic competition for the approval and listing of mRNA vaccines has entered a fierce stage.In addition to Fosun Pharma, the mRNA vaccines that Abbio is responsible for research and development, and Watson Bio is responsible for the production and promotion of mRNA vaccines are the current domesticthe firstA mRNA vaccine that has entered clinical phase III. On May 11, the Mexican Foreign Minister announced that the mRNA new crown vaccine developed by a Chinese companyARCoVWill start in Mexico on the 30th of this monthIIIPhase trial, it is estimated that 6000 volunteers will participate, thisvaccineIt is the joint research and development of the Military Academy of Sciences, Aibo Biology, Watson Biology, and the three parties.

Different from the cooperation model of Fosun Pharma, the research and development of Aibo Biological and Watson BiologicalARCoVThe vaccine has independent intellectual property rights, and itscoreThe raw materials and key equipment have been made domestically. In December 2020, Watson builds China’s first mRNA new crownvaccineProduction workshop,ARCoVThe vaccine is expected to be completed and put into production within 8 months, with a production capacity of 120 million doses per year in the first phase.

It has always been a concern in the industry that the domestically produced mRNA vaccines of Watson Biologics and Fosun Pharma will be the first to cross the line in China.Former Shanghai Center for Disease ControlvaccineExpert Tao Lina believes that Fubitai is an imported product after all. If it is successfully approved for listing in the future, it is most likely to be listed conditionally.He told Ao Yi News reporter that, in comparison, the local company Watson Biotech may have an advantage in production. “After all, it is our local Chinese company, and Fosun andBioNTechBecause of the cooperation model, it may be slower in production. ”

Regarding the localized production of Fubitai, Fosun Pharma stated that the company hasBioNTechTechnology transfer and equipment ordering are already underway.BioNTechDispatchedexpertI have gone to the Jinshan plant in Shanghai to work with the Fosun Pharma team. Both parties have a daily meeting on various professional working groups. Fosun Pharma expects that the joint venture agreement will be implemented in June 2021 and the localized production line will be completed in August.beginnormal production. According to Wu Yifang, in terms of production capacity design, considering that the production line will be transferred to other mRNA vaccines and global demand, production capacity will retain the possibility of growth.

Earlier, Abbio and its partner institutions introduced its mRNA COVID-19 vaccine in a paper published in the journal Cell in September 2020.ARCoVProduction process. The paper introduces that the aqueous solution of mRNA and the ethanol solution of lipid molecules are quickly mixed, so that the lipid molecules form LNP that encapsulates the mRNA, and then the ethanol is removed by tangential flow filtration and concentrated to obtain the original solution.

Although the above process seems simple, the founder andchiefIn an interview with the media, executive InBev pointed out that it involved the determination of a large number of process parameters.coreTechnology”. The determination of these parameters fundamentally determines the performance of the product, and only a few companies have it.

Tao Lina introduced to Ao Yi reporters that the two domestically producedvaccineThere are two differences in the technical details: Fubitel uses all the S protein of the virus asvaccineTarget ingredient, WatsonvaccineUse the RBD region on the viral S protein asvaccineTarget component. RBD is the key to the virus being able to attach to human cells. The mutation is not large. If the mutation is large, it may not be able to infect the human body.vaccineIt may be more effective in dealing with virus mutations; in addition, there are other areas on the S protein that can stimulate the body to produce antibodies. These antibodies may not have the effect of neutralizing the virus, and theoretically may also lead to ADEeffect, Which helps the virus infect the human body.So, theoretically, the RBD vaccine may be moreSafetysome.The lipid carrier used in both is LNP, but Fubitai must be cryopreserved, WatsonvaccineIt is announced that it can be stored at 2-8 degrees.

HaitongInternationalAccording to the research report, there are many difficulties in mRNA production. One is that the carrier used is usually nanometer-sized, with a diameter of usually less than 200 nanometers, so the production process is more demanding; in addition, the capping rate will also affect the activity and side effects of the product. However, the preparation process has a great influence on the stability of the product, and how to maintain the purity of the product is also a challenge. “Capping” is the process of modifying mRNA molecules.

“Fragrant Rice Cakes” in the Capital Market: What is the prospect of mRNA?

With the outbreak of the new crown epidemic in 2020, mRNA vaccines became famous in the first battle.

Former Shanghai Center for Disease ControlvaccineExpert Tao Lina told Ao Yi news reporter that in the new crownvaccinePreviously, most of the early work on mRNA vaccines focused onTumoraspect.cancerThe vaccine istreatmentSexual, not preventive, aimed atTumorPreferentially expressed by cellsTumorRelated antigens, therefore, stimulating cell-mediated immune responses can reduceTumorburden.

In this new crown epidemic, the unprecedented cooperation environment and government investment have prompted effective data and large-scale applications tovaccineProvides a conceptualverification.Government support helps manufacturers scale up at risk while gainingthe firstBatch validity data. Two foreign companies that first developed mRNA vaccines——BioNTech(Bintech),Moderna(Modena) Announced separatelyIIIClinical data,ModernaIn the clinical data of (Modena), among 30,000 vaccinators,vaccineThe effective rate is 94.5%, and the critical illness protection is 100%. November 9, 2020BioNTechofIIIPhase clinical data released, mRNA vaccineThe effective rate exceeds 90%.

Tao Lina believes that the mRNA vaccine is effective, and the corresponding vaccinators should also receive a “greater response.” “ThisvaccineTo stimulate antibody immunity and cellular immunity at the same time, and cellular immunity will release a lot of cytokines, leading to adverse reactions in the vaccinated person. “He thinks that because there are other less reactivevaccineFor reference, it is not ruled out that the people will inoculate different types of vaccines according to their own acceptance.vaccine.

Since the outbreak of the new crown epidemic, there have been many cases of cooperation between domestic pharmaceutical companies and mRNA companies:

On May 20, 2020, CanSino and Precision Canada NanoSystems(PNI) companies jointly developed a technology based on mRNA lipid nanoparticles (mRNA-LNP)vaccine；

On December 7, 2020, Zhifei Biological announced that it plans to subscribe for 10.189% of the shares of Shenxin Biological with its own funds of 35 million yuan to deploy the third-generation mRNA vaccine technology platform.

On May 9, 2021, Fosun Pharma invested 100 million U.S. dollars to cooperate with a German biotech companyBioNTechSet up a joint venture company to realize the new mRNA crownvaccineLocalized production and commercialization.

It can be said that the outbreak of the new crown epidemic has pushed the mRNA pharmaceutical industry to an unprecedented climax, and the domestic mRNA pharmaceutical industry has finally ushered in the spring of development.

Large-scale financing of mRNA technology companies has also received attention. Just at the beginning of June, Si Microbiology announced that it has officially completed a new round of financing of 200 million US dollars, breaking the record of a single financing for domestic mRNA companies.At the “2021 Pujiang Innovation Forum” held recently, Li Hangwen, founder, chairman and CEO of Sri Microbiology, stated that mRNA vaccines should have become the world’s most frequently administered vaccine.vaccine, Both in clinical trial results and in the real world have shown good results, suchvaccineIt can also be adjusted quickly to deal with virus mutations. In addition, unlike many traditionalvaccineCompared with the development route, mRNA vaccines can activate stronger cellular immunity.

Gao Fu, director of the Chinese Center for Disease Control and Prevention, once stated at an industry conference that mRNA technology is effective for infectious diseases,AIDS, Genetic diseases, rare diseases,TumorWill provide various opportunities, hoping to develop classic traditionsvaccineWhen considering the benefits that mRNA vaccines may bring to humans.

Ao Yi News reporter Lin Shiyan